Publications

Scientific Exhibit at American Epilepsy Society (AES) Annual Meeting (Dec.7, 2025)

  1. Overview of Bright Minds Biosciences. Pioneering Serotonin Pharmacology
  2. BMB-101 and Biased 5-HT2C Agonism. A Novel Approach for Sustained Epilepsy Management
  3. 5-HT2C Agonism: Multiple Animal Models Supporting the Efficacy in Developmental and Epileptic Encephalopathy (DEE) Indications
  4. 5-HT2C Agonism: Efficacy in 6-Hz and DBA/2 Mouse Models Supports Utility in Other Epilepsy Syndromes
  5. Safety, Tolerability, and Pharmacokinetics of Novel 5-HT2C Agonist BMB-101 (Phase 1 Clinical Study)
  6. A phase 1 clinical study of BMB-101 shows linear PK and a reduced rate of somnolence and GI/Urinary side effects compared to other 5-HT2C agonists
  7. BMB-101 in Absence Seizures and Developmental and Epileptic Encephalopathy (DEE): An Open-Label Phase 2 Study
  8. Selective 5-HT2C Agonist BMB-101 in the Treatment of Patients with Prader-Willi Syndrome (PWS)

American Epilepsy Society Meeting 2024.Safety, Tolerability, and Pharmacokinetics of Novel 5-HT2C Agonist BMB-101 (Phase I Clinical Study)

American Epilepsy Society Meeting 2024. BMB-101 and Biased 5-HT2C Agonism: A Novel Approach for Sustained Epilepsy Management

Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). BMB-101: A selective 5-HT2C agonist for the treatment of rare epilepsies.

Society for Neuroscience 2024 Annual Meeting (Chicago). Poster: Novel 5-HT2A selective agonists with well-characterized PK profile and short duration of action.

Society for Neuroscience 2024 Annual Meeting (Chicago), Satellite NIH Forum. Poster: Selective 5-HT2C Agonists for the Treatment of Rare Epileptic Disorders

Society for Neuroscience 2024 Annual Meeting (Chicago). Poster: Novel 5-HT2A/2C mixed and partial agonist and its efficacy in preclinical pain models